Endothelin-1 and nitric oxide in patients on chronic hemodialysis

Renal Failure

Volumn 30, Issue 9, 2008, Pages 836-842

  Tomić, Monika ^a   Galešić, Krešimir ^b   Markota, Ivica ^a  

^a UNIVERSITY OF MOSTAR   (Bosnia and Herzegovina)

^b University of Zagreb School of Medicine   (Croatia)

Author keywords

ACE inhibitors; Endothelin 1; Hemodialysis; Hypertension; Nitric oxide

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; NITRIC OXIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CASE-CONTROL STUDIES; CHRONIC DISEASE; COHORT STUDIES; ENDOTHELIN-1; FEMALE; HUMANS; HYPERTENSION; KIDNEY DISEASES; MALE; MIDDLE AGED; NITRIC OXIDE; RENAL DIALYSIS;

EID: 54249138125     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220802356218     Document Type: Article

References (48)

1. de Leeuw PW. Patophysiology of hypertension in patients in renal replacement therapy. Blood Purif. 1994;12:245-251.
2. Davies DL, Schalekamp MA, Beevers DG, et al. Abnormal relation between exchangeable sodium and the renin-angiotensin system in malignant hypertension and in hypertension with chronic renal failure. Lancet. 1973;1: 683-686.
3. Campigano JL, Ramirez-Muzo O, Ramirez-Gonzales R. Normal renin uremic hypertension: Study of cardiac hemodynamics, plasma volume, extracellular fluid volume, and the renin- angiotensin system. Arch Intern Med. 1976;136: 17-23.
4. Tuckman J, Benninger JL, Reubi F. Hemodynamics and blood volume studies in long-term haemodialysis patients and in patients with successfully transplanted kidneys. Clin Sci Mod Med. 1973;45:155-157.
5. Pollock D. Renal endothelin in hypertension. Curr Opin Nephrol Hypertension. 2000;9:157-164.
6. Stjerniguist M. Endothelins - vasoactive peptides and growth factors. Cell Tissue. 1998;292:1-9.
7. Rossi GP, Seccia TM, Albertin G, Pessina C. Mesaurment of endothelin: Clinical and research use. Ann Clin Biochem. 2000;37:608-626.
8. Benatti L, Fabbrini MS, Patrono C. Regulation of endothelin-1 biosynthesis. Ann NY Acad Sci. 1994;714:109-121.
9. Hickey KA, Rubanyi GM, Paul RJ, Highsmith RF. Characteraziation of a coronary vasoconstrictor peptide produced by cultured endothelial cells. Am J Physiol. 1985;248:550-556.
10. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1998;332:411-415.
11. Shiffrin EL. Endothelin in hypertension. Curr Op Cardiol. 1995;10:485-494.
12. Simonson MS, Dunn MJ. Renal actions of endothelin peptides. Curr Opin Nephrol Hypertens. 1993;2:51-60.
13. Bloom IZ, Bentlen FR, Wilson MA, et al. In vivo effects of endothelin on the renal microcirculation. J Surg Res. 1993;54:274-280.
14. Rabelnik TJ, Kaasjager KAH, Boer P, et al. Effects of endothelin 1 on renal function in humans. Implications for physiology and patophysiology. Kidney Int. 1994;46: 376-381.
15. Mongensen CE, Keeane WF, Bennett PH, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet. 1995;346:1080-1084.
16. Morris ST, McMurray JJ, Spiers A, Jardine AG. Impaired endothelial function in isolated human uremic resistance arteries. Kidney Int. 2001:60;1077-1082.
17. Rodrigez-Manas L, Lopez-Doriga P, Petider R, et al. Effect of glycemic control on the vascular nitric oxide system in patients with type 1 diabetes. J Hypertension. 2003;21: 1137-1143.
18. Williams SB, Cusco JA, Roddy M-A, Johnstone MT, Creager MA. Impaired nitric oxide- mediated vasodilatation in patients with non-insulin dependent diabetes mellitus. J Am Coll Cardiol. 1996;27:567-574.
19. Reyes AA, Karl IE, Klahr S. Role of arginine in health and in renal disease. Am J Physiol. 1994;267:331-346.
20. Vallance P, Leone A, Calver A, Collier J, Moncada S. Acumulation of an endogenus inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572-575.
21. Schmidt RJ, Baylis C. Total nitric oxide production is low in patients with chronic renal disease. Kidney Int. 2000;58:1261-1266.
22. Hand MF, Haynes WG, Webb DJ. Hemodialysis and L arginin but not D arginin correct renal faliure associated endothelial dysfunction. Kidney Int. 1998;53:1068-1077.
23. Kari JA, Donald AE, Vallance DT, et al. Physiology and biochemistry of endothelial function in children with chronic renal failure. Kidney Int. 1997:52;468-472.
24. Morris ST, McMurray J, Rodger R, Jardine AG. Impaired endothelinum-dependent vazodilatation in uremia. Nephron Dial Transplant. 2000;15:572-575.
25. Vallance P, Leone A, Calver A, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572-575.
26. Madore F, Prudhomme L, Austin JS, et al. Impact nitric oxide in blood pressure in hemodialysis patients. Am Kidney Dis. 1997;30:665-671.
27. Potter GS, Johnson RJ, Fink GD. Role of endothelin in hypertension of experimental chronic renal failure. Hypertension. 1997;1578-1584.
28. Bussemaker E, Passauer J, Reimann D, Schulze B, Reichel W, Gross P. The vascular endothelin system is not overactive in normotensive hemodialysis patients. Kidney Int. 2002;62:940-948.
29. Nims RW, Darbyshire JF, Saavedra JE, et al. Colorimetric methods for the determination of nitric oxide concentration in natural aqueous solutions. Methods. 1995;7:48-54.
30. Raj DSC, Vincent B, Simpson K, et al. Hemodynamic changes during hemodylisis: Role of nitric oxide and endothelin. Kidney Int. 2002;61:697-704.
31. Goddard J, Johnston NR, Hand MF, et al. Endothelin-a receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure. Circulation. 2004;109:1186-1193.
32. Ottosson-Seeberger A, Alhorbg G, Hemsen A, et al. Hemodialysis effects of endothelin-1 and big endothelin-1 in chronic hemodialysis patients. J Am Soc Nephrol. 1999;10:1037-1044.
33. Hand MF, Haynes WG, Webb DJ. Reduced endogenous endothelin-1 mediated vascular tone in chronic renal failure. Kidney Int. 1999;55:613-620.
34. Demuth K, Blacher J, Guerin AP, et al. Endothelin and cardiovascular remodelling in end- stage renal disease. Nephrol Dial Transplant. 1998;13:375-383.
35. Nabokov AV, Smann K, Wessels A, et al. Endothelin receptor antagonists influence cardiovascular morphology in uremic rats. Kidney Int. 1999;55:512-519.
36. Morris ST, McMurray JJ, Rodger R, Jardine AG. Impaired endothelium-dependent vasodilatationem in uremia. Nephrol Dial Transplant. 2000;15:572-575.
37. Ross R. The patogenesis of atherosclerosis. A perspective for the 1990. Nature. 1993;362:801-809.
38. Haynes WG, Hand MF, Dockrell MEC, et al. Physioogical role of nitric oxide in regulation of renal function in humans. Am J Physiol. 1997;272:364-371.
39. Blum M, Yachnin T, Wollman Y, et al. Low nitric oxide production in patients with chronic renal failure. Nephron. 1998;79:265-268.
40. Schmidt RJ, Yokota S, Tracy TS, Sorkin MI, Baylis C. Nitric oxide production is low in end-stage renal disease patients on peritoneal dialysis. Am J Phisiol Renal Phisiol. 1999;276:794-797.
41. Vallance PA, Leone A, Calver J, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572-575.
42. Klahr S. The role of nitric oxide in hypertension and renal disease progression. Nephrol Dial Transplant. 2001;16:60-62.
43. Ashab I, Peer G, Blum M, et al. Oral administration of L-arginine and captopril in rats prevents chronic renal failure by nitric oxide production. Kidney Int. 1995;47:1515-1521.
44. Aiello S, Noris M, Todeschini M, et al. Renal and systematic nitric ocxide synthesis in rats with renal mass reduction. Kidney Int. 1997;52:171-181.
45. Vaziri ND, Ni Z, Wang XQ, Ovejsi F, Zhou XI. Downregulation of nitric oxide synthesis in chronic renal insufficiency: Role of excess PTH. Am J Physiol. 1998;274:642-649.
46. Kovac T, Barta J, Kossis B, Nagy J. Nitric oxide in IgA nephropathy patients with or without hypertension. Exp Nephrol. 1005;3:369-372.
47. Schmidt RJ, Domico J, Samsel LJ, et al. Indices of activity of the nitric oxide system in patients on hemodialysis. Am J Kidney. 1999;34:228-234.
48. Kielstein JT, Boger RH, Bode-Boger SM, et al. Asymmetric dimetylarginine plasma concentration differ in patients with end stage renal disease: Relationship to treatment method and atherosclerosis disease. J Am Soc Nephrol. 1999;10:594-600.